Merit Medical Systems, Inc.
Chief Regulatory Affairs Officer
John Knorpp is Chief Regulatory Affairs Officer at Merit Medical Systems. In this role, he directs all global Regulatory and Medical Affairs activities which includes worldwide regulatory submissions and clinical trials. John completed a Bachelor's of Science degree at Brigham Young University specializing in Statistics- Quality Science and an MBA from the University of Utah. Previously he was employed by CR Bard as Director of Regulatory. He has been in the medical device industry since 1996.
Vice President Business Development
George Hamilton, Intermountain Healthcare - Chairman of BioUtah Board of Directors Mr. George Hamilton serves as Vice President of Business Development for Intermountain Healthcare and provides multifaceted expertise to BioUtah as Vice Chairman of the Board.. From a community entrepreneurial investment arm, Mr. Hamilton leads a variety of innovative projects designed to benefit Intermountain's patients and stakeholders, and to drive growth in Utah's economy life science community.
Edwards Lifesciences LLC
Corporate Vice President, Public Affairs
Dirksen J. Lehman has been corporate vice president, public affairs, since June 2013. He joined the company in 2007 as vice president of government affairs, and later added responsibility for global health economics and reimbursement. In his current role, Lehman continues to oversee these functions and also has responsibility for global communications, corporate branding, and global corporate giving. Prior to joining Edwards, he was head of the healthcare practice at Clark & Weinstock, a government affairs and crisis management consulting firm in Washington, D.C. Lehman has also served in The White House as special assistant to the president for legislative affairs, and health counsel for the majority on the U.S. Senate HELP Committee. Lehman received his undergraduate degree from Millersville University of Pennsylvania and his law degree from Catholic University of America.
Clene Nanomedicine, Inc.
CEO and President
Rob Etherington has held a variety of roles in 20+ years in the pharmaceutical industry. Rob is former senior VP, commercial operations at Actelion Pharmaceuticals US, Inc. helping grow it into a $7+ billion market-cap company with nearly $2 billion in annual sales. Rob also served as an officer of Actelion and on the US Executive Board. Before joining Actelion, Rob served as a marketing leader at Pfizer with key responsibilities in the launch years for Lipitor and Rezuliin. Rob is an alumnus of the Harvard Business School General Management Program, and he holds an MBA from the Marriott School at Brigham Young University. He joined BioUtah's Board of Directors in April 2016.
University of Utah
John Langell, MD, PhD, MPH completed his surgical training at Stanford University Medical Center and completed advanced training in Space and Aerospace Medicine with NASA at the Johnson Space Center in Houston, TX. He has specialized expertise in the treatment of diseases of the upper gastrointestinal tract, biliary tract and endocrine system. He currently serves as Chief of General Surgery at the George E Wahlen VA Medical Center and Executive Director for the CMI at the University of Utah.
Dinesh and Kalpana Patel Foundation
Dr. Dinesh Patel is a Managing Director of Patel Family Investments, a venture capital fund. Previously, Dr. Patel served as President & CEO of TheraTech, Inc. He has founded/co-founded several companies including Ashni Naturaceuticals, Salus Therapeutics and OneCare. Dr Patel has been the recipient of multiple awards including BioUtah's Willem J. Kolff Lifetime Achievement Award. He was on the USTAR Governing Authority and currently is Chairman of the Board at The Leonardo.
Vice President of Government Affairs
Kim has years of health care policy experience directly in government as well as within the life science industry. She joined Myriad in 2011 to build a Government Affairs Department. As VP of Government Affairs, Kim oversees the company's federal and state government affairs and policy activities with a focus on reimbursement, FDA and patent policy. Prior to Myriad, Kim spent ten plus years in federal government affairs for various life science organizations including Eli Lilly, Amgen, OSI Pharmaceuticals and PhRMA. She received her bachelor degree from Franklin & Marshall College.
Richard Ji is VP of Infusion Therapy Systems at Becton, Dickinson & Co. He has global responsibility for the Infusion Therapy Business, which is a significant portion of the $2.3 billion Medical Surgical Unit. He joined BD close to 20 years ago. His experiences range from managing start-up operations, shutdown operations; productions early in their life cycles to products late in their lifecycles; and turnaround situations. Richard holds a Bachelor of Science in Manufacturing Engineering from Brigham Young University and a MBA from Duke University – Fuqua School of Business. His wife Karen and he have 3 children. He joined BioUtah’s Board in April 2016.